Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. 1997

C M van der Horst, and M S Saag, and G A Cloud, and R J Hamill, and J R Graybill, and J D Sobel, and P C Johnson, and C U Tuazon, and T Kerkering, and B L Moskovitz, and W G Powderly, and W E Dismukes
Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, 27599-7030, USA.

BACKGROUND Treatment with low-dose amphotericin B (0.4 mg per kilogram of body weight per day) or oral azole therapy in patients with the acquired immunodeficiency syndrome (AIDS) and cryptococcal meningitis has been associated with high mortality and low rates of cerebrospinal fluid sterilization. METHODS In a double-blind multicenter trial we randomly assigned patients with a first episode of AIDS-associated cryptococcal meningitis to treatment with higher-dose amphotericin B (0.7 mg per kilogram per day) with or without flucytosine (100 mg per kilogram per day) for two weeks (step one), followed by eight weeks of treatment with itraconazole (400 mg per day) or fluconazole (400 mg per day) (step two). Treatment was considered successful if cerebrospinal fluid cultures were negative at 2 and 10 weeks or if the patient was clinically stable at 2 weeks and asymptomatic at 10 weeks. RESULTS At two weeks, the cerebrospinal fluid cultures were negative in 60 percent of the 202 patients receiving amphotericin B plus flucytosine and in 51 percent of the 179 receiving amphotericin B alone (P=0.06). Elevated intracranial pressure was associated with death in 13 of 14 patients during step one. The clinical outcome did not differ significantly between the two groups. Seventy-two percent of the 151 fluconazole recipients and 60 percent of the 155 itraconazole recipients had negative cultures at 10 weeks (95 percent confidence interval for the difference in percentages, -100 to 21). The proportion of patients who had clinical responses was similar with fluconazole (68 percent) and itraconazole (70 percent). Overall mortality was 5.5 percent in the first two weeks and 3.9 percent in the next eight weeks, with no significant difference between the groups. In a multivariate analysis, the addition of flucytosine during the initial two weeks and treatment with fluconazole for the next eight weeks were independently associated with cerebrospinal fluid sterilization. CONCLUSIONS For the initial treatment of AIDS-associated cryptococcal meningitis, the use of higher-dose amphotericin B plus flucytosine is associated with an increased rate of cerebrospinal fluid sterilization and decreased mortality at two weeks, as compared with regimens used in previous studies. Although consolidation therapy with fluconazole is associated with a higher rate of cerebrospinal fluid sterilization, itraconazole may be a suitable alternative for patients unable to take fluconazole.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005437 Flucytosine A fluorinated cytosine analog that is used as an antifungal agent. 5-Fluorocytosine,Alcobon,Ancobon,Ancotil
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000666 Amphotericin B Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela. Amphocil,Amphotericin,Amphotericin B Cholesterol Dispersion,Amphotericin B Colloidal Dispersion,Fungizone

Related Publications

C M van der Horst, and M S Saag, and G A Cloud, and R J Hamill, and J R Graybill, and J D Sobel, and P C Johnson, and C U Tuazon, and T Kerkering, and B L Moskovitz, and W G Powderly, and W E Dismukes
September 1997, The American journal of medicine,
C M van der Horst, and M S Saag, and G A Cloud, and R J Hamill, and J R Graybill, and J D Sobel, and P C Johnson, and C U Tuazon, and T Kerkering, and B L Moskovitz, and W G Powderly, and W E Dismukes
February 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
C M van der Horst, and M S Saag, and G A Cloud, and R J Hamill, and J R Graybill, and J D Sobel, and P C Johnson, and C U Tuazon, and T Kerkering, and B L Moskovitz, and W G Powderly, and W E Dismukes
March 1997, NIAID AIDS agenda,
C M van der Horst, and M S Saag, and G A Cloud, and R J Hamill, and J R Graybill, and J D Sobel, and P C Johnson, and C U Tuazon, and T Kerkering, and B L Moskovitz, and W G Powderly, and W E Dismukes
December 1995, NIAID AIDS agenda,
C M van der Horst, and M S Saag, and G A Cloud, and R J Hamill, and J R Graybill, and J D Sobel, and P C Johnson, and C U Tuazon, and T Kerkering, and B L Moskovitz, and W G Powderly, and W E Dismukes
February 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
C M van der Horst, and M S Saag, and G A Cloud, and R J Hamill, and J R Graybill, and J D Sobel, and P C Johnson, and C U Tuazon, and T Kerkering, and B L Moskovitz, and W G Powderly, and W E Dismukes
January 1992, The New England journal of medicine,
C M van der Horst, and M S Saag, and G A Cloud, and R J Hamill, and J R Graybill, and J D Sobel, and P C Johnson, and C U Tuazon, and T Kerkering, and B L Moskovitz, and W G Powderly, and W E Dismukes
November 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
C M van der Horst, and M S Saag, and G A Cloud, and R J Hamill, and J R Graybill, and J D Sobel, and P C Johnson, and C U Tuazon, and T Kerkering, and B L Moskovitz, and W G Powderly, and W E Dismukes
January 1992, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology,
C M van der Horst, and M S Saag, and G A Cloud, and R J Hamill, and J R Graybill, and J D Sobel, and P C Johnson, and C U Tuazon, and T Kerkering, and B L Moskovitz, and W G Powderly, and W E Dismukes
August 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
C M van der Horst, and M S Saag, and G A Cloud, and R J Hamill, and J R Graybill, and J D Sobel, and P C Johnson, and C U Tuazon, and T Kerkering, and B L Moskovitz, and W G Powderly, and W E Dismukes
March 1992, The New England journal of medicine,
Copied contents to your clipboard!